[Prevention of hepatitis B flare-up using lamivudine in a patient with non-Hodgkin's lymphoma after allogeneic bone marrow transplantation].
A 22-year-old man with non-Hodgkin's lymphoma (B-cell lymphoblastic lymphoma, Stage IVA) received chemotherapy and radiation therapy and achieved complete remission. He was admitted for allogeneic bone marrow transplantation (BMT) using a graft from his completely HLA-matched mother. Although he had HBV infection, allogeneic BMT was performed because he still had normal liver function and strongly requested the procedure. He developed both acute and chronic GVHD after the procedure, but showed no liver damage related to HBV. Treatment with lamivudine (150 mg/day) was started because the HBV-DNA level increased gradually after allogeneic BMT. Although the HBV-DNA then decreased gradually and there was no evidence of severe liver damage, the patient died following relapse of NHL. It seems that in this case, treatment of HBV with lamivudine may have prevented serious liver damage after allogeneic BMT. Therefore, allogeneic BMT may be done safely in patients with HBV infection if lamivudine is administered.
Sunami
K
K
Department of Internal Medicine, National Okayama Hospital.
Fujiwara
T
T
Yoshida
C
C
Fujii
S
S
Fukuda
S
S
Sezaki
T
T
D000328:Adult; D016026:Bone Marrow Transplantation; D006509:Hepatitis B / Q000517:prevention & control*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D016393:Lymphoma, B-Cell / Q000628:therapy*; D008297:Male; D011184:Postoperative Period; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine